Sopharma AD (BUL:SFA)

Bulgaria · Delayed Price · Currency is BGN · Price in EUR

1.925

+0.035 (1.85%)

At close: Jul 31, 2026

54.37% (1Y)

Market Cap	1.95B +60.0%
Revenue (ttm)	2.68B +20.1%
Net Income	154.80M +81.5%
EPS	0.44 +172.9%
Shares Out	528.43M
PE Ratio	8.36
Forward PE	n/a
Dividend	0.06 (1.52%)
Ex-Dividend Date	Jul 9, 2026

Volume	4,119
Open	1.890
Previous Close	1.890
Day's Range	1.890 - 1.925
52-Week Range	1.226 - 2.000
Beta	0.08
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; ... [Read more]

Industry Pharmaceutical Preparations

Founded 1933

Employees 6,005

Stock Exchange Bulgarian Stock Exchange

Ticker Symbol SFA

Full Company Profile

Financial Performance

In 2025, Sopharma AD's revenue was 1.35 billion, an increase of 22.31% compared to the previous year's 1.10 billion. Earnings were 68.30 million, an increase of 74.61%.

Financial numbers in EUR Financial Statements